GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (NAS:PRQR) » Definitions » Cyclically Adjusted PS Ratio

ProQR Therapeutics NV (ProQR Therapeutics NV) Cyclically Adjusted PS Ratio : 23.63 (As of May. 24, 2024)


View and export this data going back to 2014. Start your Free Trial

What is ProQR Therapeutics NV Cyclically Adjusted PS Ratio?

As of today (2024-05-24), ProQR Therapeutics NV's current share price is $1.89. ProQR Therapeutics NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.08. ProQR Therapeutics NV's Cyclically Adjusted PS Ratio for today is 23.63.

The historical rank and industry rank for ProQR Therapeutics NV's Cyclically Adjusted PS Ratio or its related term are showing as below:

PRQR' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 23.4   Med: 34   Max: 57.5
Current: 25.42

During the past years, ProQR Therapeutics NV's highest Cyclically Adjusted PS Ratio was 57.50. The lowest was 23.40. And the median was 34.00.

PRQR's Cyclically Adjusted PS Ratio is ranked worse than
86.56% of 506 companies
in the Biotechnology industry
Industry Median: 5.675 vs PRQR: 25.42

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ProQR Therapeutics NV's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.059. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.08 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


ProQR Therapeutics NV Cyclically Adjusted PS Ratio Historical Data

The historical data trend for ProQR Therapeutics NV's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV Cyclically Adjusted PS Ratio Chart

ProQR Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 32.58

ProQR Therapeutics NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.45 34.81 26.25 32.58 30.01

Competitive Comparison of ProQR Therapeutics NV's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, ProQR Therapeutics NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProQR Therapeutics NV's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Cyclically Adjusted PS Ratio falls into.



ProQR Therapeutics NV Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

ProQR Therapeutics NV's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.89/0.08
=23.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, ProQR Therapeutics NV's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.059/128.5800*128.5800
=0.059

Current CPI (Mar. 2024) = 128.5800.

ProQR Therapeutics NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 99.240 0.000
201409 0.000 99.960 0.000
201412 0.000 99.050 0.000
201503 0.000 99.750 0.000
201506 0.000 100.230 0.000
201509 0.000 100.500 0.000
201512 0.000 99.730 0.000
201603 0.000 100.310 0.000
201606 0.000 100.260 0.000
201609 0.000 100.570 0.000
201612 0.000 100.710 0.000
201703 0.000 101.440 0.000
201706 0.000 101.370 0.000
201709 0.000 102.030 0.000
201712 0.000 101.970 0.000
201803 0.000 102.470 0.000
201806 0.000 103.100 0.000
201809 0.000 103.950 0.000
201812 0.000 103.970 0.000
201903 0.000 105.370 0.000
201906 0.000 105.840 0.000
201909 0.000 106.700 0.000
201912 0.000 106.800 0.000
202003 0.000 106.850 0.000
202006 0.000 107.510 0.000
202009 0.000 107.880 0.000
202012 0.000 107.850 0.000
202103 0.000 108.870 0.000
202106 0.004 109.670 0.005
202109 0.015 110.790 0.017
202112 0.003 114.010 0.003
202203 0.017 119.460 0.018
202206 0.014 119.050 0.015
202209 0.011 126.890 0.011
202212 0.011 124.940 0.011
202303 0.009 124.720 0.009
202306 0.016 125.830 0.016
202309 0.018 127.160 0.018
202312 0.044 126.450 0.045
202403 0.059 128.580 0.059

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ProQR Therapeutics NV  (NAS:PRQR) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


ProQR Therapeutics NV Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ProQR Therapeutics NV (ProQR Therapeutics NV) Business Description

Traded in Other Exchanges
Address
Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.